COVID-19 in Older Adults- A Practical Review for Emergency Providers in 2022

Michael L Malone, MD, Teresita M Hogan, MD, FACEP, Alice Bonner, PhD, RN, FAAN, Kevin Biese, MD, Patti Pagel, RN, Kathleen T Unroe, MD, MHA

ABSTRACT

COVID-19 has posed a considerable threat to all aspects of older Americans’ lives. The pandemic generated acute illness, emergency department (ED) visits, hospitalization, respiratory failure, and death. Pandemic-associated social isolation and loneliness further endangered older adults. Recovery from COVID-19 illness has commonly been followed by chronic symptoms, which may also precipitate ED visits. While vaccination has mitigated risks of serious illness requiring hospitalization, a booster dose is required to sustain protection. New treatments and therapies, including monoclonal antibodies and antiviral agents, have shown efficacy for older adults who are at risk of hospitalization. Older adults remain vulnerable in 2022, after two years of the COVID-19 pandemic. Emergency care for older patients is now challenged with health system staffing shortages and diminished access to care in community programs & skilled nursing facilities. This article attempts to synthesize the avalanche of discovery and innovation into a narrative review focused on the emergency and immediate post ED care of the aging adult patients both during and as a result of the COVID-19 pandemic.

Box 1: Patient Scenario 1

An Older Patient Presents to the ED for Treatment

A 79-year-old Laotian woman who lives in the community with her family was seen by her primary care provider at a routine follow-up visit in early January 2022. She was noted to have a cough with congestion. She had no loss of smell and no gastrointestinal symptoms. She had no known sick contacts.

Past Medical History: Diabetes mellitus, osteoarthritis, peripheral neuropathy, depression, osteopenia, subclinical hypothyroidism, and hypertension. She received a COVID vaccination (Feb and March 2021) but did not get a booster dose. She needed assistance for bathing but otherwise was independent in her self-cares.

Medications include: lisinopril 5 mg daily, metformin XR 500 mg daily, vitamin D 2,000 units daily, atorvastatin 20 mg daily, meclizine 12.5 mg daily prn, and gabapentin 100 mg each night. BP 173/96. Pulse 89/ minute. Pulse ox=97% on room air. Respiratory rate= 20 per minute. Temperature= 98.6. BMI= 25. Physical examination was remarkable for normal attention and level of consciousness. Her cardio-pulmonary examination was normal. Her COVID-19 test in the primary care office was positive.

• Which medication or treatment could be considered?
• How would you counsel the patient regarding her co-morbid illnesses?
BACKGROUND

During the last two years of the COVID-19 pandemic, the emergency department (ED) has been the interface between our community and our health care system. As of March 13, 2022, over 79.5 million cases and 967,711 deaths have been attributed to COVID-19 in the United States (US). This paper will provide key points about COVID-19 in older adults for emergency medicine providers, as exemplified in the case scenarios (Boxes 1 and 2). We will present a succinct review of COVID-19 epidemiology in older adults and review the presentation of both acute illness and the sequelae of COVID-19 illness. We will review reports of vaccination protection in older adults, ED treatment strategies, and the implications of COVID-19 on systems of care affecting older patients. Finally, we will describe the impact of the pandemic on the ED workforce.

EPIDEMIOLOGY

Age is associated with severe COVID-19 outcomes. More than 54.1 million people are aged ≥ 65 years in the US. In 2020 these older persons suffered 81% of U.S. COVID-19 related deaths, and as of September 2021, their mortality was over 80 times greater than those aged 18-29 years. Although residents in long-term care facilities made up < 1% of the U.S. population, those residents suffered 16% of all COVID-19 deaths. Additionally, the COVID-19 mortality risk and disease severity associated with any high-risk condition increases with age. Lastly, older adults infected with COVID-19 were more likely than younger adults to require hospitalization, develop pulmonary failure, and need either non-invasive or invasive ventilation.

Box 2: Patient Scenario 2

An Older Patient Presents to the ED with a Cascade of Symptoms and Functional Decline after COVID-19

A 73-year-old community-dwelling woman was brought to the ED by her daughter who reports that the patient had a decline in function and cognition after her recent hospital discharge. Her daughter reports having trouble managing her at home. The patient was noted to be sleeping all day, and not eating. She was generally weak and complained of pain in both of her legs. She missed her most recent dialysis, as she was too tired. She required two family members to assist with transfers. Prior to her hospitalization, she required only one person to assist.

Fourteen days ago, her family brought her to the ED 3 days after testing positive for COVID-19. She received no vaccination for COVID-19. At that time, her symptoms included a runny nose, cough productive of green sputum, and nausea. There was no hypoxia. She had missed dialysis once due to difficulty coordinating care with active COVID-19 infection. Her initial admission labs were significant for hypokalemia and hyponatremia. Physical therapy and occupational therapy noted a decline from her baseline function. Her recent hospital length of stay was 3 days.

Past Medical History: Multiple co-morbidities included ESRD (receiving dialysis on T/Th/S), dementia, cerebrovascular accident, atrial fibrillation, coronary artery disease with NSTEMI in 2020, hypertension, osteoarthritis, and protein-calorie malnutrition. Her multiple medications included apixaban.

Social history was notable for the daughter being her paid personal care provider.

The ED was overcrowded with 20 boarding admitted patients.

- What are common problems for older patients with recent COVID-19 infections?
- How would you determine the best strategy to help this older patient and her family caregivers?
- How do we access community and long-term services to support this patient and family caregiver?
ACUTE PRESENTATION OF COVID-19 IN OLDER ADULTS

COVID-19 is a multi-organ disease and therefore causes a broad spectrum of signs and symptoms.12 COVID-19 patients typically exhibit nonspecific symptoms of both upper and lower respiratory infection along with occasional nausea, vomiting, and diarrhea. One population screening study of 1,279 people demonstrated that fever, ageusia (loss of sense of taste), and weakness increased the odds of infection, while 36% of people testing positive were asymptomatic.13

In a Cochrane review of 44 studies, including 10 from the ED, only cough and fever had a sensitivity of at least 50% for COVID-19 illness.14 These studies used a positive RT-PCR as the reference standard, as well as clinical expertise and imaging. The presence of anosmia (loss of sense of smell) or ageusia had sensitivities below 50% but, specificities of 93%. However, the majority of signs and symptoms heralding potential COVID-19 infection had very poor diagnostic accuracy. Neither the presence nor absence of commonly attributed COVID-19 symptoms were accurate enough to be predicative or capable of excluding active illness. However, simple fever and cough may be useful to identify people for further testing, and the presence of anosmia or ageusia can serve as “red flags” for acute illness. There is a paucity of solid evidence for diagnosis of COVID-19 in older adults. COVID-19 signs and symptoms along with most serious infections in this population such as bacterial pneumonia, and urinary sepsis, all lead to non-specific presentations. The older adult’s presenting signs and symptoms can be used with diagnostic testing during the acute presentation in the ED. Notably, however, a negative RT-PCR test does not rule out COVID-19 and should not be used as the sole basis for treatment or management decisions. A false-negative test could occur if testing was performed too early or too late to make an accurate diagnosis with the RT-PCR.15

The categorization of potential illness into actionable groups based on illness severity is more impactful to the emergency clinician.16,17 Mild or moderate illness symptoms include fever, cough, aches, and lethargy without dyspnea at rest. Severe symptoms include dyspnea, tachypnea, and hypoxia, with features ranging from pneumonia to acute respiratory distress syndrome (ARDS), shock, or other organ dysfunctions. Kennedy and colleagues documented that delirium often existed without any other typical signs or symptoms of COVID-19 infection.18 Delirium was also associated with poor hospital outcomes and death. Delirium should therefore be considered as an indication for screening, testing, and evaluation for COVID-19 infection in older adults.

LONG-HAUL PRESENTATION OF COVID-19 IN OLDER ADULTS

Descriptions of post-acute sequelae lasting beyond 12 weeks have been termed post-COVID-19 syndrome or long-haul COVID.19 Long-haul COVID incidence is predictably rising following high rates of omicron infection. Easy fatigability is the most common symptom of this COVID-19 complication. One study noted fatigability in 51% of those with long COVID findings. Anxiety, dyspnea, and headache were each noted in 38%.20 Most studies followed a cohort of patients 60 days after their diagnosis, symptom onset, or hospitalization; or for 30 days after their recovery or hospital discharge. Studies typically use surveys imaging and/ or diagnostic clinical assessments outside of the ED.21 ED physicians and nurses should be aware that in some patients, symptoms may persist long after recovery from COVID-19. To make the diagnosis of long haul COVID-19 in older adults in the ED, the clinician would need to assess for a functional decline during the COVID-19 illness or find an acute illness that could explain the symptoms.

In one bit of favorable news for older adults, they are less likely than the younger cohort to experience post- COVID psychological distress such as PTSD, depression, and anxiety.22 Older adults generally exhibit higher levels of resilience to pandemic-related psychological stress.23,24 In cognitively intact older adults, age may buffer COVID-19 related mental health deterioration.25 Yet the harms of social isolation were not examined in these studies.

Older adults demonstrate higher rates of cognitive difficulties, persisting for months after discharge from COVID-19 hospitalization.26 New onset dementia has been noted in about 2% of patients...
over age 65 in the first 14-90 days post-COVID-19 diagnosis. This new dementia may cause increased ED presentations and require increased home supports to allow ED discharge. Enhanced access to cognitive screening from the ED should be considered for older adult COVID-19 survivors. Further research of long-haul COVID-19 will need to be integrated into ongoing research on ED dementia care.

**TREATMENTS AND MANAGEMENT IN THE ED**

**Therapy**

The use of ethical principles such as maximizing benefit to the greatest number, preventing harm, and mitigating health inequities, may allow ED prioritization for access to new therapies with limited availability. Shared decision-making in the ED is fundamental during the care of older adults. ED providers have learned from pandemic resource shortages that the time to develop these strategies is before the next wave of illness outpaces resources.

The ED management of COVID-19, as with all illnesses, focuses first on stabilization of life threats. In COVID-19, the first and most important mainstay of treatment is supplemental oxygen. Supplemental oxygen can render patients eupneic, greatly reducing the potential for respiratory exhaustion. Advanced age is associated with a high risk of pulmonary failure, need for mechanical ventilation, and death. Age ≥ 85 years, dyspnea, and polypharmacy are important predictors of mortality. The amount of supplemental oxygen reaching the alveoli maximizes at a FiO2 of 44%, with flows in excess of 6L. FiO2 can be increased to 100% when used with a 10-15L/min flow rate. Oxygen delivery may be further increased by high flow nasal cannula (HFNC) devices, which maintain FiO2 at 100% while increasing flow to as much as 60L/min. The use of high-flow oxygen through a nasal cannula significantly decreased the need for mechanical ventilation support and time to clinical recovery compared with conventional low-flow oxygen use.

If patients remain hypoxemic despite maximal therapy with HFNC, they are typically placed on higher levels of support such as CPAP or invasive mechanical ventilation (IMV). One study showed HPNC use effectively prevented IMV in 71.4% of patients. Another study showed that one-third of hypoxic COVID-19 patients on HFNC did not require intubation. Cochrane review determined that HFNC likely improves treatment compared to standard oxygen but makes little or no difference to treatment failure compared to NIV or NIPPV. Comfort is of particular importance in tolerating any therapy in cognitively impaired individuals. It is important that improvement in either short-term or long-term comfort with HFNC proved of very low certainty. Among patients with severe COVID-19, HFNC seems to be an effective and safe treatment modality in acute respiratory failure.

**Vaccination**

A paucity of older individuals was studied in published and ongoing phase II-III randomized clinical trials evaluating COVID-19 vaccine efficacy. We know older people suffered the highest consequences of morbidity and mortality from COVID-19. They were also the first population to be vaccinated. This resulted in a large population available for a vaccine efficacy study. However, only 9.83% of any study participants were ≥ 65 years, 1.66% ≥ 75 years, and < 1% were ≥ 85 years. Also striking is the lack of studies supporting the efficacy and safety of COVID-19 vaccines on older persons with frailty, disability, or living in long-term care facilities. A recent study examined the immunogenicity and adverse reactions of BNT162b2 mRNA vaccines in older adults with frailty or living in long-term care facilities. The vaccine produced immunogenicity, independent of age, or level of frailty and co-morbidity. The small sample size and inclusion criteria are cause, however, for further study.

As of March 13, 2022, 91.3% of adults aged 65 to 74 years and 85.6% of adults age ≥ 75 years are fully vaccinated for COVID-19. The immunization of older people with either mRNA or vector-based vaccines decreased the likelihood of severe cases needing ICU care by more than 90%. In adults ≥ 50 years two doses of mRNA vaccine demonstrated 89% effectiveness against laboratory-confirmed infection requiring hospitalization, 90% effectiveness against ICU admission, and 91% effectiveness regarding ED
or urgent care clinic visit. Two vaccine doses provided protection in persons ≥ 85 years varying from 81-85% for hospitalization, ED, or urgent care clinic visits. Given the concern for impaired immune response with aging these data are encouraging.48 Vaccinations did not entirely prevent post-vaccination COVID-19 infections, termed breakthrough infections. Seventy percent of breakthrough infections requiring hospitalization occurred in adults ≥ 65 years. Older persons also accounted for 87% of breakthrough mortality.49 However, the majority of breakthrough infections in post-vaccinated patients were mild or asymptomatic.50

Boosters
In older patients, the risk of COVID-19 illness increases six months after the initial vaccination. Decreased protection against hospitalization and death was greater in those ≥ 65 years at 20 weeks or more after vaccination. Greater waning of effectiveness against hospitalization was noted with the delta variant and with the increase of clinical vulnerability.

However, booster vaccination rapidly induces a recurrent and robust immune response. This was found across all ages, with older adults defined as age ≥ 60 years of age.51-54 The administration of a third COVID-19 mRNA vaccine dose improved protection against COVID-19 associated hospitalization.55 Omicron variant infection outcomes were also improved by booster vaccination doses. As of January 8, 2022, infection incidence and hospitalization, and mortality rates were lowest in those having booster doses.56 People receiving a booster at least 5 months after a second vaccine dose had 90% lower COVID-19 mortality.57 Rates of severe illness were lower in the ages ≥ 60 years booster group, by a factor of 21.7%.51 Importantly, longer intervals between doses provided higher serologic responses and increased vaccine effectiveness.58 An optimal dosage interval has yet to be reported. Heterologous boosting is defined as the administration of the booster dose from a different manufacturer than was given in the primary series. Heterologous vaccination in all adults, including those > 61 years, resulted in more robust immune responses than homologous boosting and might enhance protection.59

On March 15, 2022, Pfizer and BioNTech sought authorization from the Food and Drug Administration for a second COVID-19 booster shot for older Americans.60 Several strategies have been suggested to enhance vaccination acceptance in older adults. The Society of Academic Emergency Medicine presents resources for overcoming barriers to vaccination.17 Additionally, healthcare workers can enhance vaccination in this population by the incorporation of known communication strategies, questions, and prompts.61 Novel vaccine platforms and adjuvant systems should be considered to enhance the vaccination in older adult populations.62 We encourage ED systems to routinely offer COVID vaccination, especially since EDs routinely provide vaccination for illnesses of far less public health impact, such as tetanus.17 The offer of a vaccine for respiratory transmissible infection may have greater acceptance in patients presenting to the ED with concern, but testing negative for, the illnesses of influenza or COVID. Lastly, a global strategy enhancing older adult immunization as part of a public health agenda could decrease the suffering for the billions of older persons at risk of death and disability from vaccine-preventable diseases.63

TREATMENT RESOURCES FOR ED PROVIDERS
Therapies for the treatment of COVID-19 are still in development with no effective curative therapy yet available. Table 1 describes COVID-19 treatment and resources for older adults.17,64-70 Most of the guidelines and websites describe evidence-based care, without overtly defining older adult considerations. The Infectious Disease Society of America site,65 and the WHO site,68 note specific older adult considerations. The geriatrics portion of the American College of Emergency Physicians COVID-19 Management tool,64 provides information from the early pandemic. The Society of Academic Emergency COVID Provider Toolkit,17 provides succinct communication strategies, as well as interactive treatment recommendations. Finally, a side-by-side tool from the Health and Human Services is a clinician-friendly,
Table 1: COVID-19 Treatment and Resources for Older Adults

<table>
<thead>
<tr>
<th>Resource</th>
<th>Date Updated</th>
<th>Geriatric EM Centeredness</th>
<th>Components of the Resource</th>
<th>Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEP COVID-19 Field Guide 64</td>
<td>July 13, 2021</td>
<td>Geriatrics section from early in the pandemic.</td>
<td>One chapter in this resource was specific to older adults-social isolation; inter-facility transfers.</td>
<td><a href="https://www.acep.org/coronavirus/covid-19-field-guide/cover-page/">https://www.acep.org/coronavirus/covid-19-field-guide/cover-page/</a></td>
</tr>
<tr>
<td>Infectious Disease Society of America Real-Time Learning 65</td>
<td>March 8, 2022</td>
<td>Geriatrics section updated November 9, 2021.</td>
<td>Geriatrics was included within patient populations. Key areas included delirium, frailty, dementia, and clinical features plus resources.</td>
<td><a href="https://www.idsociety.org/covid-19-real-time-learning-network/">https://www.idsociety.org/covid-19-real-time-learning-network/</a></td>
</tr>
<tr>
<td>NIH COVID-19 Treatment Guidelines 66</td>
<td>March 2, 2022</td>
<td>The approach for older adults was integrated into the guidelines, but not defined in special populations. A succinct description was provided on follow-up after ED care.</td>
<td>Table and clear outline helped to synthesize the treatments, the setting of care, the recommendations, and the certainty of evidence.</td>
<td><a href="https://www.covid19treatmentguidelines.nih.gov/">https://www.covid19treatmentguidelines.nih.gov/</a></td>
</tr>
<tr>
<td>The European Society of Clinical Microbiology and Infectious Diseases COVID-19 Living Guidelines 67</td>
<td>February 1, 2022</td>
<td>No specific recommendations for older adults in special populations. The approach to older adults was not integrated into the guidelines.</td>
<td>Regularly updated guidelines with detailed data tables which provide a synthesis of evidence. Clinical questions focused on population, intervention, comparison, and outcomes (PICO). Difficult to navigate the resource tables.</td>
<td><a href="https://www.essentialmedicine.org/clinicalmicrobiologyandinfectiousdiseases/covid19-living-guidelines/">https://www.essentialmedicine.org/clinicalmicrobiologyandinfectiousdiseases/covid19-living-guidelines/</a></td>
</tr>
<tr>
<td>WHO Living COVID-19 Guideline 68</td>
<td>November 23, 2021</td>
<td>A thoughtful and succinct area of this guideline described practical considerations for assessment and care of older adults with COVID-19.</td>
<td>A detailed website with guidelines in the context of care. The summary of recommendations was helpful. Ratings of evidence and ratings of recommendations were provided.</td>
<td><a href="https://www.who.int/publication-detail/who-2019-nCoV-clinical-2021-guideline">https://www.who.int/publication-detail/who-2019-nCoV-clinical-2021-guideline</a></td>
</tr>
<tr>
<td>Society of Academic Emergency Medicine COVID-19 Provider Toolkit 17</td>
<td>January 3, 2022</td>
<td>Strategies to improve communication with older adults are integrated into the materials. Treatment recommendations are not specific for older adults.</td>
<td>This interactive website provides (evidence-based) succinct treatment recommendations as well as strategies to improve communication with patients who have COVID-19.</td>
<td><a href="https://www.sae.org/education/saeem-online-academic-resources/covid-19-provider-toolkit">https://www.sae.org/education/saeem-online-academic-resources/covid-19-provider-toolkit</a></td>
</tr>
</tbody>
</table>
Monoclonal Antibody (mAb) Treatments

Monoclonal antibody (mAb) treatment is associated with decreased hospitalization and death in outpatients with mild to moderate COVID-19. Older age is an indication for mAb treatments. These treatments are especially important for ED providers discharging patients home with mild to moderate COVID-19 symptoms. We will not describe the mAb treatments which are not likely to be active against the omicron variant and limit our focus to sotrovimab.

- Sotrovimab treatment has resulted in a 79-85% reduction in hospitalization or death in high-risk adult outpatients compared to placebo. This drug has activity against the Delta variant and is likely active in the Omicron variant. Sotrovimab, similarly to the other mAb treatments, is authorized only for the treatment of lab-confirmed mild to moderate disease within ten days of symptom onset. See Table 2.
- Monoclonal antibody treatments are an effective treatment for those with laboratory-confirmed COVID-19 who are ≥65 years. Additionally, they may be used for younger patients at high risk of progressing to severe illness. See important details that refer to eligible populations. These treatments are NOT authorized for hospitalized patients nor for those who require oxygen therapy. Recommendations for monoclonal antibody medication are often made at a regional/local level, based on the treatment that best covers local variants.

Therapy with monoclonal antibodies changes rapidly subject to the latest available evidence and guidance of the Center for Disease Control. These therapeutics are distributed via the HHS Office of the Assistant Secretary for Preparedness and Response transitioned to a State and Territory-coordinated Distribution System for mAbs.

Oral Antivirals

- Paxlovid has shown an 88% reduction of hospitalization or death for high-risk patients if given within 5 days of symptom onset. It has known activity in the Delta variant and data is pending on Omicron variant activity. Table 2 highlights the high risk of drug-drug interactions and comorbid illnesses which is relevant to older adults. The percentage of older adults in the clinical trial was low.
- Molnupiravir has shown a 30% reduction of hospitalization and death for high-risk patients if given within 3 days of symptom onset. It has known activity in the Delta variant and data is pending on Omicron variant activity. In a phase 3 trial of 1,433 persons who were unvaccinated with mild to moderate laboratory-confirmed COVID illness and at least one high risk factor for severe disease, molnupiravir reduced the risk of hospitalization or death when started within 5 days of symptoms. The effectiveness of molnupiravir is competitive to the three monoclonal antibodies remdesivir and nirmatrelvir-ritonavir, with a relatively lower cost. An FDA expert panel review showed that molnupiravir with 50% hospitalization reduction was inferior to the three existing monoclonal antibody cocktails having over 60% efficacy. However oral availability and decreased expense of molnupiravir lead to ultimate approval recommendation. Table 2 highlights the low rate of older adults in the clinical trial of this medication.

Other Treatments

- Remdesivir has mixed data on efficacy against COVID disease progression. One study shows that a 3-day course resulted in 30% of patients >60 years with 87% lower hospitalization risk or death, and an acceptable safety profile. Please see Table 2. Another trial concluded that remdesivir shortened the time to recovery in hospitalized patients with lower respiratory tract infections. However, a Cochrane review found moderate certainty that remdesivir has little or no effect on all-cause mortality at up to day 28 in hospitalized adults with SARS-CoV-2 infection. Finally, one study showed an association with longer hospital stays.
• Convalescent Plasma (CP) some studies demonstrated that early administration of high-titer CP reduced the progression of COVID-19 in mildly ill older adults. An October 2020 Cochrane review update detailed the uncertainty of the benefit of CP treatment. Finally, a December 2021 scoping review included 154 studies- with 112 studies concluding CP is safe and resulted in clinical improvement.

• Steroids, in patients hospitalized with COVID-19, the use of 6 mg daily of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or supplementary oxygen, but not among those who did not need respiratory support. In the RECOVERY study no benefit of the use of steroids was observed in patients of older age or higher number of co-morbidities. The use of dexamethasone resulted in a 30% reduction in 28-day mortality among patients receiving invasive mechanical ventilation compared to the usual care group. No benefit was found among patients not requiring respiratory support. The WHO strongly recommends corticosteroids (i.e., dexamethasone, hydrocortisone, or prednisone) for the treatment of patients with severe and critical COVID-19.

Table 2: COVID-19 Treatments for Older Adults

<table>
<thead>
<tr>
<th>Setting</th>
<th>Treatment</th>
<th>Percent of Older Adults in Clinical Trials</th>
<th>*Benefits/ Harms</th>
<th>Nuances for Older Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED + Hospital</td>
<td>High-flow O₂</td>
<td>No detail provided on % age &gt;=65 years.</td>
<td>NNT= 6 to avoid 1 endotracheal intubation in adults with acute respiratory failure and severe COVID-19.</td>
<td>High-flow oxygen therapy in the ED and intensive care unit decreases the need for endotracheal intubation and shortens the time of clinical recovery in severe COVID-19 when compared to conventional low-flow oxygen therapy.</td>
</tr>
<tr>
<td></td>
<td>Monoclonal antibodies sotrovimab</td>
<td>22% were age &gt;=65 years and 11% were &gt;=70 years.</td>
<td>NNT=16.7 to prevent 1 hospitalization for any cause or death. Harms: Approximately 1% risk of transfusion-related reaction.</td>
<td>For the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Treatment should be given as soon as possible, within 10 days of onset of symptoms. No adjustment for renal function. Must have immediate access to medications to treat severe infusion reactions/anaphylaxis.</td>
</tr>
<tr>
<td>ED + Outpatient</td>
<td>Oral Antiviral Paxlovid nirmatrelvir/ ritonavir</td>
<td>13% were age &gt;=65 years and 3% were &gt;=75 years.</td>
<td>NNT=17.5 to prevent 1 hospitalization for any cause through day 28. Harms: No deaths in the treatment group and 1.6% deaths in patients receiving placebo.</td>
<td>For mild to moderate COVID-19 in adults with a positive test for the virus, who are at high risk for progression to severe COVID-19 including, hospitalization and death. Start as soon as possible following diagnosis, and within 5 days of symptom onset. Renal dosing required. Avoid in eGFR &lt;30 ml/min. Multiple/serious drug-drug interactions related to ritonavir a strong cytochrome P450 (CYP) 3A4 inhibitor metabolism.</td>
</tr>
<tr>
<td>ED + Outpatient</td>
<td>Oral Antiviral molnupiravir</td>
<td>34% were aged &gt;=50 years. Median age=43.0 years.</td>
<td>NNT= 14.7 to prevent 1 hospitalization for any cause or death through day 29.</td>
<td>For treatment of mild to moderate COVID-19.</td>
</tr>
<tr>
<td>ED infusion</td>
<td>Early intravenous remdesivir daily for 3 days.</td>
<td>30% were aged &gt;=60 years. Mean age= 50.0 years.</td>
<td>NNT= 21.7 to prevent 1 hospitalization for COVID-19 through day 28. Harms: adverse events occurred in 12.2% of the remdesivir group and 8.8% of the placebo group. For symptomatic non-hospitalized patients with COVID-19 who are at high risk of disease progression.81</td>
<td></td>
</tr>
</tbody>
</table>

*The number needed to treat was calculated from each original citation. The control group outcome minus the intervention group outcome was equal to the absolute risk reduction. The number needed to treat is the inverse of the absolute risk reduction.*

**PSYCHO-SOCIAL IMPLICATIONS FOR OLDER ADULTS DURING THE PANDEMIC**

Social isolation and loneliness have been important health challenges for older adults during the COVID-19 pandemic.90, 91 Social isolation and loneliness are major risk factors linked with poor physical and mental health status. Mandates for stay at home and social distancing have exacerbated social isolation and loneliness. Economic insecurity, difficulty accessing health care services, and racial inequities compound the situation. Some innovative voice-controlled intelligent technologies have been implemented to counteract COVID-era loneliness.92 Emergency medicine physicians seldom recognize social isolation and its detrimental impact on the daily lives of vulnerable older adults.93

Many older adults presenting to the ED may not have left home or had any interaction with a medical provider for weeks to months. The ED is often the site where family caregivers turn when they are unable to care for their loved ones. Efforts to identify medical problems are improved by an assessment of the individuals’ social supports and their access to community resources. Knowledge of these supports is critical for safe discharge in this population.

If the ED assessment shows that the patient does not require admission to the hospital, it is imperative providers understand the availability of current community resources. The pandemic has limited available usual resources, especially personnel. Typical orders for home care or other support services may not be available. A shortage of resources is a common theme. Community programs may be in short supply, including non-medical home care, transportation, community meal sites, behavioral health programs, in-person counseling, and aging services from the county to support family caregivers. Skilled home care agencies have, likewise, faced an increase in referrals with a lack of staff to provide the services. Table 3 shows how ED physicians can access community resources for older adults. Knowing and acting on what matters most to the older person honors the individual’s choices.94

**CARING FOR INDIVIDUALS WITH ALZHEIMER’S DISEASE OR RELATED DEMENTIAS**

The number of older adults in the U.S. living with dementia or related disorders has increased with continued rise projected in the coming decades.95, 96 Therefore, ED teams are increasingly more likely to evaluate and treat individuals living with dementia.97

Individuals living with cognitive challenges often experience negative effects from busy ED environments. Loud noises, bright lights, overcrowding, and long waits to be seen, admitted, or discharged may all contribute to sensory overload and increased anxiety. In addition, building rapport quickly with unfamiliar providers may be difficult for individuals with mild, moderate, or advanced dementia.98 These challenges have precipitated the need to improve dementia care in the ED and the evidence base on which to provide that care. GEAR 2.0 ADC provides recommendations for screening, communication, best care practices, and care transitions.28

COVID-19, isolation, and limited social interactions have contributed to reduced physical activity, depression, and loneliness among older adults and care partners.99, 100 Limited physical activity and social

---

**Table 3**

| Control Group Outcome | Intervention Group Outcome | Harms: No safety concerns when compared to placebo. | Start as soon as possible following diagnosis, and within 5 days of symptom onset. Renal dosing not required. |

| Mean age= 50.0 years. | NNT= 21.7 to prevent 1 hospitalization for COVID-19 through day 28. Harms: adverse events occurred in 12.2% of the remdesivir group and 8.8% of the placebo group. For symptomatic non-hospitalized patients with COVID-19 who are at high risk of disease progression.81 |

Range 18-90 years. | Renal dosing not required. | Early intravenous remdesivir daily for 3 days. | Patients were enrolled across 101 hospitals. Dosing was given for 5 days. The adverse events rate was compared to placebo. |

Mean age= 50.0 years. | Renal dosing not required. | Early intravenous remdesivir daily for 3 days. | Patients were enrolled across 101 hospitals. Dosing was given for 5 days. The adverse events rate was compared to placebo. |

Harms: adverse events occurred in 12.2% of the remdesivir group and 8.8% of the placebo group. For symptomatic non-hospitalized patients with COVID-19 who are at high risk of disease progression.81 | Start as soon as possible following diagnosis, and within 5 days of symptom onset. Renal dosing not required. | Early intravenous remdesivir daily for 3 days. | Patients were enrolled across 101 hospitals. Dosing was given for 5 days. The adverse events rate was compared to placebo. |

Harms: No safety concerns when compared to placebo. | Start as soon as possible following diagnosis, and within 5 days of symptom onset. Renal dosing not required. | Early intravenous remdesivir daily for 3 days. | Patients were enrolled across 101 hospitals. Dosing was given for 5 days. The adverse events rate was compared to placebo. |

Harms: adverse events occurred in 12.2% of the remdesivir group and 8.8% of the placebo group. For symptomatic non-hospitalized patients with COVID-19 who are at high risk of disease progression.81 | Start as soon as possible following diagnosis, and within 5 days of symptom onset. Renal dosing not required. | Early intravenous remdesivir daily for 3 days. | Patients were enrolled across 101 hospitals. Dosing was given for 5 days. The adverse events rate was compared to placebo. |

Harms: No safety concerns when compared to placebo. | Start as soon as possible following diagnosis, and within 5 days of symptom onset. Renal dosing not required. | Early intravenous remdesivir daily for 3 days. | Patients were enrolled across 101 hospitals. Dosing was given for 5 days. The adverse events rate was compared to placebo. |
isolation also contribute to accelerated cognitive decline. As a result, family stress levels are heightened. Care partner capacity often influences whether or not a person living with dementia is taken to the ED or if they can return to their home or community safely.

The challenges of living with an older adult who is experiencing symptoms related to dementia have increased, and many care partners accompanying a person with dementia to the ED show signs and symptoms of weariness, anxiety, and exhaustion. In some cases, family or other care partners become ill themselves or are unable to find a paid caregiver due to the current staffing crisis.

Unfortunately, while many low or no-cost programs and services exist in most communities, ED staff members may not be aware of them, or may not have resources to make helpful referrals to support families. An interprofessional team approach has been effective where social workers or care managers assist in providing information on community resources and follow up with primary care providers and/or dementia specialists. Reduced social worker or care manager hours in the ED limits patient or care partner access to the individuals on the team who are most familiar with community services such as Area Agencies on Aging (AAAs), senior centers, nutrition programs, home care agencies, and others. Table 3 provides online search tools for local community resources for older patients and their family caregivers.

<table>
<thead>
<tr>
<th>Table 3: Community Resources to Safely Assist Older Adult Returning Home from the Emergency Department</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Resource</strong></td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td>ElderCare Locator</td>
</tr>
<tr>
<td>Older Veterans Services</td>
</tr>
<tr>
<td>Alzheimer’s Association</td>
</tr>
<tr>
<td>Find Help.org</td>
</tr>
</tbody>
</table>

**CHALLENGES FOR RESIDENTIAL CARE CENTERS AND IMPLICATIONS FOR TRANSITIONS**

Recruiting and retaining qualified staff, particularly clinical staff providing hands-on care, has been a challenge in nursing facilities and assisted living facilities for many years. High rates of staffing turnover in positions of nurses and nurse aides, are well documented and have been correlated with quality concerns, including citations related to infection control. A recent article found that the average annual turnover rate for total nursing staff in these facilities was 128%. Now, the situation is even more critical. As in many healthcare settings, burnout has led to clinical staff leaving the front lines. In addition, nursing facilities are competing with hospitals and staffing agencies that are offering significant financial incentives. While most nursing facility staff have received the COVID-19 vaccine, some staff have left employment in certain facilities due to vaccine mandates. A small, 50-bed nursing home may...
only have four nurses on staff and if two are unvaccinated and choose to leave their jobs this can have a significant impact on that facility.

Inadequate staffing contributes to increased ED transfers. Staffing levels may also impact the ability of nursing facilities to receive patients from the ED or following a hospital stay. While the overall census of most nursing facilities is down, which would indicate a capacity for additional patients, short staffing forces some administrators to pause taking admissions. Patients who are COVID positive can be discharged to nursing facilities, and facilities often create dedicated COVID wings or sections. Depending on whether they have an active outbreak and ability to dedicate staff to the COVID unit, a given facility may decline to accept these transfers. This can lead to longer wait times for patients prior to discharge and have a ripple effect on ED and hospital bed capacity. Further, a patient who meets the criteria for nursing facility level care may refuse to transfer to the setting, which can also delay discharge planning.

Table 4 provides a checklist of factors the ED should consider before transferring back to a long-term care facility. Older adults are particularly vulnerable to adverse events during such care transitions. These may include adverse drug events or medication errors, falls, abuse or neglect, pressure ulcers, and dehydration. The use of systematic approaches, such as checklists and warm handoffs, and calling the next site of care to ensure a coordinated transition, is even more essential.

<table>
<thead>
<tr>
<th>Checklist Item</th>
<th>Succinct Rationale</th>
<th>Mitigation Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Stable vital signs and oxygenation.</td>
<td>An indicator of the severity of illness, co-morbid conditions, and response to treatment.</td>
<td>Observe or admit; provide oxygen.</td>
</tr>
<tr>
<td>2. The patient’s advance directives.</td>
<td>A clear indicator of who is making the health decisions.</td>
<td>Clarify and honor how the patient wants to receive care.</td>
</tr>
<tr>
<td>3. “What matters most in the individual’s health?”</td>
<td>Understand the patient’s preferences and develop a care plan that matches.</td>
<td>Review advanced directives and discuss with the patient.</td>
</tr>
<tr>
<td>4. Provider understanding of which site in the long-term care setting patient receives care.</td>
<td>Multiple services may be available within many retirement facilities.</td>
<td>Consult social services to define where the individual receives care and what is needed/available after the ED visit.</td>
</tr>
<tr>
<td>5. Adequate staffing available at the long-term care facility.</td>
<td>Staffing levels at the outlying facility may block their ability to receive patients back from the ED.</td>
<td>Real-time communication strategies to clarify: if the facility can receive patients; contact information; policies.</td>
</tr>
<tr>
<td>6. Cognition and function back to baseline.</td>
<td>Delirium and functional decline are common during acute illness and COVID-19.</td>
<td>Screen for delirium and avoid transfer for those with delirium. Assess baseline and current function and avoid transfer for those with significant new functional change.</td>
</tr>
<tr>
<td>7. Able to eat and drink and take medications.</td>
<td>Loss of the ability to take oral intake blocks hydration, nutrition, and management of co-morbid conditions.</td>
<td>Observe or admit.</td>
</tr>
<tr>
<td>8. Access to new medications.</td>
<td>Inability to start new medications from the ED would block the initiation of a care plan.</td>
<td>Have a list of long-term care sites and meds available.</td>
</tr>
<tr>
<td>9. Follow up in a timely manner.</td>
<td>Inability to provide follow-up of a new condition would block the ability to monitor the response to a new treatment.</td>
<td>Communicate with the primary care provider and describe the care plan.</td>
</tr>
<tr>
<td>10. Communicate with a warm handoff, prior to transfer back.</td>
<td>A succinct description of what was found and the care plan.</td>
<td>A quick call to the long-term care facility or secure chat in the electronic health record.</td>
</tr>
</tbody>
</table>
CHALLENGING ASPECTS FOR EMERGENCY DEPARTMENT STAFF

During the COVID-19 pandemic, frequently changing recommendations and requirements from the CDC, CMS, individual state departments of public health, and other agencies have created a particular challenge for the care of patients who are in acute distress, unstable, and require immediate, life-saving treatments. Optimizing ED staff and patient safety under those conditions challenges our daily use of personal protective equipment (PPE), types and fit of masks, and frequency of staff testing. Additional issues are caused due to the availability of testing and treatment resources, vaccination and booster requirements, and other public health measures.

ED physicians and nurses, know that the last two years of serving on the frontline of an increasingly strained health care system has been exhausting. Our patients are sick, tired from long waits to be seen, and then are often boarding excessive amounts of time in the ED. It has been challenging if not impossible to care for them in the ways we want and which they deserve.

Our hospitals are strained to the breaking point and often unable to admit those requiring admission nor to support ED staff in managing patients to the extent needed. Many of the community resources we depend on for patient support have closed during COVID-19. We have been asked to keep visitors out of the ED, often causing confrontational conversations with patients’ loved ones. All the while we are worried about getting ill ourselves from a poorly understood or infecting our loved ones with a potentially deadly virus. There are no perfect answers but here are a few best practices shared by our ED colleagues from around the world.

Take care of yourself (self-wellness).

Emergency physicians now rate the highest amongst all specialties in burnout and depression. The same may well be true for emergency nurses. We need to recognize just how hard our jobs currently are and take time for wellness activities. Also, we need to encourage our colleagues to do the same.

Bring caregivers in.

Caregivers (care partners) are not visitors. Patients, especially patients with cognitive impairment, need their caregivers. The caregiver is often the ED staff’s best ally and will help in the provision of collateral history as well as in the care of the patient. Caregivers can provide re-orientation, assist with feeding and toileting to decrease delirium development in older patients and stress on ED staff. Help your hospital recognize that caregivers are not visitors by allowing appropriately screened caregivers into the ED with PPE.

Enable everyone on the team to work at the top of their license.

There are many skilled individuals that can help ED performance if we let them. Some EDs are bringing paramedics into the ED to help place IV lines and administer medications. Other EDs are using medical or nursing students as vulnerable patient ambassadors who can help ensure that those without caregivers have their needs met. Look around and see who your system can offer to help you. While ED staff often assist with any and all patient care functions as part of the team, it is not optimal to have physicians drawing or sending labs, nor nurses cleaning floors. Keeping professionals functioning at their maximal professional capacity and having adequate support personnel is our goal for both optimal ED functioning and professional satisfaction.

CONCLUSION

The COVID-19 pandemic has greatly impacted ED care of older adults. Nonspecific symptoms and alterations of mental status are common presentations in both acute and long-haul COVID-19. Categorization into disease severity groups is useful for both treatment and disposition.
Supplemental oxygen is a mainstay of ED stabilization and applies equally to older persons. Vaccinations and boosters are lifesaving and reduce ED visits, especially in those most vulnerable. Strategies to maximize vaccination acceptance and ED distribution of vaccines in older adults should be implemented.

ED providers must have access to multiple external sources to help incorporate the constantly evolving treatments and recommendations, such as monoclonal antibodies and oral antivirals into ED practice. These treatments are particularly useful in the care of older adults with mild to moderate illnesses.

Psychosocial implications, care of those with dementia, and transitions to residential centers are subjects that must be understood by emergency providers in order to provide competent care and dispositions. The optimizing of professional functioning within the ED and maintaining both self-care and care of your colleagues are important for the day-to-day survival of emergency providers under pandemic-induced stress.

**Box 3: Patient Follow Up of Box 1- An Older Patient Presents to the ED for Treatment**

- **Which medication or treatment could be considered?**
  This patient had acute onset of symptoms within a few days of presenting to her primary care provider for a routine visit. She had laboratory-confirmed testing for COVID-19. Her vital signs, including pulse oximetry, were normal. There was no sign of delirium, no functional decline, and no worsening of her co-morbid illnesses. The patient had received her vaccination but did not receive her booster. Her age and co-morbidities put her at risk for severe disease. In this case, sotrovimab was available and was administered in the ED. Oral molnupiravir would have been an alternative treatment strategy.

- **How would you counsel the patient regarding her co-morbid illnesses?**
  This patient was counseled to continue with her routine medications and monitoring of her blood glucose. Her primary care provider used a secure chat feature in the electronic health record to coordinate a follow-up visit in her office. The patient was encouraged to schedule a COVID-19 booster in the community pharmacy in the next week. Her family was provided the CDC website for guidance regarding their own testing and mask use.

**Box 4: Patient Follow Up of Box 2- An Older Patient Presents to the ED for Treatment**

- **What are common problems for older patients who have recently had COVID-19 infections?**
  Fatigue, anxiety, dyspnea, and headache are noted as common problems for those who have had COVID-19. These symptoms may be attributed to the long-term scenario of COVID-19. In addition, older adults who have had an acute illness are at risk of functional decline, with or without a COVID-19 illness. Further, a functional decline of an older adult may signal an acute illness or an exacerbation of an underlying condition. A careful history, vital signs, a directed physical examination, and diagnostic evaluation are in order. The ED clinician should concurrently direct attention to her complaint of pain in her legs.

- **How would you determine the best strategy to help this older patient and her family caregivers?**
  This individual has several “red flags” which pose risk for her care. She has multiple co-morbid illnesses including dementia and end-stage renal disease. She has not received her COVID-19 vaccination or booster and this poses a particular risk for serious illness. She has missed dialysis in the context of her COVID-19 status. Now she needs more help in transferring from her bed. Her daughter expresses caregiver strain. The best strategy in the ED is to define the underlying problems contributing to her decline. The patient’s preferences for care should be elicited and “What matters most?” Likewise, define if the patient has an advance directive.

- **How do we access community and long-term services to support this patient and family caregiver?**
  In this case, the first determination would be if she needs to be admitted or not. The daughter could further describe efforts to access dialysis care. The ED staff should get a sense if the family is able and interested in having the patient return home. With the ED boarding status, a social worker and physical therapist should be consulted while the patient is in the ED.
KEYWORDS
COVID-19, older adult, emergency department care, treatment

AFFILIATIONS

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Biese, MD</td>
<td>University of North Carolina Medical School</td>
</tr>
<tr>
<td>Alice Bonner, PhD, RN, FAAN</td>
<td>Institute for Healthcare Improvement</td>
</tr>
<tr>
<td>Teresita Hogan MD, FACEP</td>
<td>University of Chicago Medical Center</td>
</tr>
<tr>
<td>Michael Malone, MD</td>
<td>Advocate Aurora Health</td>
</tr>
<tr>
<td>Patti Pagel, MSN RN GCNS-BC</td>
<td>Advocate Aurora Health</td>
</tr>
<tr>
<td>Kathleen Unroe, MD, MHA</td>
<td>Indiana University School of Medicine IU Center for Aging Research, Regenstrief Institute</td>
</tr>
</tbody>
</table>

AUTHOR CONTRIBUTIONS

**Corresponding Author:** Michael L. Malone, MD: (414) 588-2991, Email: michael.malone.md@aah.org.

**Sponsor Role:** There were no sponsors of this work.

**Funding:** There was no funding for this work.

CONFLICTS OF INTEREST

Michael L. Malone owns stock in Abbott Labs and Abbvie. The authors have declared no conflicts of interest for this article.

ACKNOWLEDGMENTS

The authors thank the John A. Hartford Foundation and the West Health Institute for their support for improving emergency care for older Americans.

REFERENCES


52. Minjie Li, Juan Yang, Lin Wang, et al. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. medRxiv 2021.08.03.21261544; doi:10.1101/2021.08.03.21261544v1


